Veradigm Inc. (MDRX)

$10.60 -$0.15 (-1.40%) 3:25 AM 12/11/24
NASDAQ | $USD | Health Information Services

Stock Data

  • Market Cap

    $1.18B
  • Day's Range

    $10.00 - $10.75
  • Volume

    -
  • 52 Week Low / High

    $5.01 - $11.80
  • PE Ratio

    11.06x
  • PEG Ratio

    2.42
  • Dividend Frequency

    -

MDRX's Dividend
$5.23
Amount
-
Dividend Yield
Oct 17
Payment Date
-
Annual Dividend Amount
Dividend Streak
Hypothetical 10k Investment Jan 1, 2020
Capital Growth
Dividend Return to Date
Dividend Payout year Est.
Expenses
Total Return
Total Return %
Analyists Ranking
1
Strong Buy
1
Buy
2
Hold
0
Sell
0
Strong Sell
$17.50
Target Price

Company News

  • Veradigm Inc (MDRX) Announces Strategic Acquisition of ScienceIO to Enhance AI Capabilities — Feb 28th, 2024

    Acquisition Announcement: Veradigm Inc (NASDAQ:MDRX) to acquire ScienceIO, a leading healthcare AI platform, for $140 million. Strategic Growth: The acquisition aims to leverage ScienceIO's AI technology on Veradigm's extensive data set to improve healthcare outcomes and lower costs. Finan...

  • Veradigm to Acquire ScienceIO — Feb 27th, 2024

    Veradigm to Leverage ScienceIO’s Leading Healthcare Artificial Intelligence (AI) Platform on the Company’s Large-Scale, High-Quality Data Set to Build Advanced, Private Language Models for Healthcare Expected to Provide Highly Differentiated and More Advanced Products to Veradigm Cust...

  • Veradigm to Participate in TD Cowen Annual Health Care Conference — Feb 28th, 2024

    CHICAGO, February 28, 2024--(BUSINESS WIRE)--Veradigm Inc. (NASDAQ: MDRX), a leading provider of healthcare data and technology products and solutions, today announced that Dr. Yin Ho, Veradigm interim Chief Executive Officer, and Lee Westerfield, interim Chief Financial Officer, will pres...

  • Veradigm Provides Update on its Financial Restatement Process — Feb 27th, 2024

    Expects Not to File Required Financial Statements by Nasdaq’s February 27, 2024 Deadline Working Diligently to File Required Financial Statements and Restore Listing Adopts Limited Duration Stockholder Rights Plan CHICAGO, February 27, 2024--(BUSINESS WIRE)--Veradigm Inc. (NASDAQ: MDR...

  • Veradigm Reveals New Insights on the Prevalence of Cardiovascular Conditions in the U.S. — Feb 20th, 2024

    Using de-identified data for 53 million unique cardiovascular patients, the report examines prevalence across all 50 states and a variety of demographics CHICAGO, February 20, 2024--(BUSINESS WIRE)--Which region of the U.S. has the highest rates of hypertension, coronary artery disease an...

  • Veradigm to Highlight New EHR-Integrated Care Gap Alert Solution at ViVE 2024 Conference — Feb 22nd, 2024

    Recently debuted Veradigm Payer Insights is delivering care cap alerts to thousands of providers and growing fast as demand for payer-provider interoperability continues to increase CHICAGO, February 22, 2024--(BUSINESS WIRE)--Veradigm Inc. (NASDAQ: MDRX), a leading provider of healthcare...

Similar Stocks

Want to be notified on dividend changes?

Start manging your portfolio today.

Sign up for free